Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Issue : The Pharmaceutical Journal, 3/10 January 2015, Vol 294, No 7843/4

Sort by: Newest first Oldest first A-Z Z-A

  • NICE recommendations for ulcerative colitis Subscription

    18 DEC 2014 10:53

    The National Institute for Health and Care Excellence (NICE) has recommended Remicade (infliximab; Merck Sharp & Dohme), Humira (adalimumab; Abbvie) and Simponi (golimumab; Merck Sharp & Dohme), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to conventional therapy, including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical ...

  • Orap in pregnancy Subscription

    18 DEC 2014 10:50

    The summary of product characteristics for Orap (pimozide; Janssen) now states that the drug should not be administered to women of childbearing potential, particularly during the first trimester of pregnancy, unless, in the opinion of the physician, the expected benefits of the drug to the patient outweigh the potential risk to the foetus.

  • Prostap QT prolongation Subscription

    18 DEC 2014 10:47

    The summary of product characteristics for Prostap (leuprorelin; Takeda) has been updated to warn that androgen deprivation therapy may prolong the QT interval, therefore patients with a history of QT prolongation, those with risk factors for QT prolongation and patients receiving drugs that might prolong QT interval should be assessed before starting treatment. 

  • Migard side effects Subscription

    18 DEC 2014 10:45

    Adverse reactions gathered after post-marketing experience have been added to the summary of product characteristics for Migard (frovatriptan; A Menarini). This includes hypersensitivity reactions, such as angioedema and anaphylaxis, and myocardial infarction and arteriospasm coronary, with unknown frequency.  

  • Calpol skin reactions Subscription

    18 DEC 2014 10:44

    The summary of product characteristics for Calpol (paracetamol; McNeil) infant oral suspension now states that patients should be informed about the signs of serious skin reactions, and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity. 

  • Drug driving laws Subscription

    18 DEC 2014 10:42

    The Department for Transport has asked pharmacies to help drivers understand the drug driving laws that come into effect in 2015. As part of a campaign to raise awareness of the new laws, from February 2015 pharmacy teams can display posters and provide leaflets to customers in the pharmacy. A ‘partner pack’ has been developed that helps explain the new rules. Pharmacy owners can

  • New Faculty submission dates Subscription

    18 DEC 2014 10:00

    The Royal Pharmaceutical Society (RPS) Faculty is in its second year and, having listened to members’ and assessors’ opinions, the Faculty team would like to offer two assessment submission dates during 2015: Sunday 26 April 2015, midnight Sunday 29 November 2015, midnight

  • Women with a history of mental health problems should receive additional support before, during and after their pregnancy, according to guidance issued by the National Institute for Health and Care Excellence (NICE)

    Pregnant women at risk of mental health problems need more support, says NICE Subscription

    17 DEC 2014 17:05 By Debbie Andalo

    Women with a history of mental health problems should receive additional support before, during and after their pregnancy, according to new NICE guidance.

  • Xtandi new indication Subscription

    17 DEC 2014 16:58

    Xtandi (enzalutamide; Astellas) is now indicated for the treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated, according to the updated summary of product characteristics. Xtandi was previously only indicated for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed ...

  • E-cigarettes can be effective smoking cessation aids, Cochrane review suggests

    E-cigarettes can be effective smoking cessation aids, Cochrane review suggests Subscription

    17 DEC 2014 16:00 By Debbie Andalo

    E-cigarettes that contain nicotine can help people quit smoking long-term or reduce the number of cigarettes they smoke compared with products that do not contain nicotine, say Cochrane reviewers.

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.